Northfield Laboratories Inc. Announces Third Quarter 2006 Financial Results Webcast

Northfield Laboratories Inc. (Nasdaq: NFLD), announced
today that the Company will host its second quarter 2006 earnings
conference call with the financial community on Tuesday, April 11,
2006, at 11:00 a.m. Eastern Time (10 a.m. Central Time).
   This call is being webcast by Thomson/CCBN and can be accessed at
Northfield's Web site at http://www.northfieldlabs.com. A replay will
be available in the same location for two weeks following the call.
   The webcast is also being distributed through the Thomson
StreetEvents Network to both institutional and individual investors.
Individual investors can listen to the call at
http://www.fulldisclosure.com, Thomson/CCBN's individual investor
portal, powered by StreetEvents. Institutional investors can access
the call via Thomson's password-protected event management site,
StreetEvents (http://www.streetevents.com ).
   Investors may also dial 866.800.8652 and enter the passcode
28793528. A replay of the call will be available by dialing
888.286.8010 and entering the passcode 83238803.

   About Northfield Laboratories

   Northfield Laboratories Inc. is a leader in developing an
oxygen-carrying resuscitative fluid, PolyHeme(R), for the treatment of
urgent, large volume blood loss in trauma and resultant surgical
settings. PolyHeme(R) is a solution of chemically modified human
hemoglobin that requires no cross matching and is therefore compatible
with all blood types. It has a shelf life in excess of 12 months.
Enrollment is currently underway in a pivotal Phase III study of
PolyHeme(R) beginning in the pre-hospital setting. For further
information about Northfield Laboratories, visit
www.northfieldlabs.com.

   This press release may contain forward-looking statements
concerning, among other things, Northfield's future business plans and
strategies and clinical and regulatory developments affecting our
PolyHeme blood substitute product. These forward-looking statements
are identified by the use of such terms as "intends," "expects,"
"plans," "estimates," "anticipates," "should," "believes" and similar
terms. These forward-looking statements involve inherent risks and
uncertainties. Our actual results may therefore differ materially from
those predicted by the forward-looking statements because of various
factors and possible events, including our ability to obtain FDA
approval to market PolyHeme commercially, the availability of capital
to finance our clinical trials and ongoing business operations, our
ability to obtain adequate supplies of raw materials and to
manufacture PolyHeme in commercial quantities, our ability to market
PolyHeme successfully, the possibility that competitors will develop
products that will render PolyHeme obsolete or non-competitive, our
ability to protect our intellectual property rights, the possibility
   that we may be subject to product liability claims and other legal
actions, our dependency on a limited number of key personnel, the
uncertainty of Fourth, Final party reimbursement for our product and
other risks and uncertainties described from time to time in our
periodic reports filed with the Securities and Exchange Commission,
including our most recently filed quarterly report on Form 10-Q and
annual report on Form 10-K. These forward-looking statements speak
only as of the date of this press release. We do not undertake any
obligation to update or publicly release any revisions to
forward-looking statements to reflect events, circumstances or changes
in expectations after the time such statement is made. All subsequent
written and oral forward-looking statements attributable to Northfield
or any person acting on our behalf are qualified by this cautionary
statement.